Nuvation Bio held their 4th quarter conference call today to update investors, on the progress of their cancer drug development programs. Just some key points below, as they will be a multi-year investment, with updates along the way.
- 4th quarter revenue of $41 million, a combination of product and license
- Net loss of $36 million, or 0.11 cents per share with 344 million shares outstanding
- The company is well funded with $529 million in cash and equivalents
- Partner Eisai to file for Ibtrozi ROS1 approval in EU by mid-year 2026
- SIGMA safusidenib 40 patient exploratory cohort, grade 3 oligodendroglioma study with readout expected in 2027
- No revenue guidance announced by the company at this time
The stock has been stable, trading in the $5.00 to $6.00 per share range in the last month, with chart below. Thank you for reading.
No comments:
Post a Comment